A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy.
One hundred and seventy-five children with Stage 3 or 4 neuroblastoma who had obtained a good response to conventional therapy were randomly allocated to 13-Cis retinoic acid at a dose of 0.75 mg/kg/day or placebo for up to 4 years. Toxicity was mild but no advantage in event-free survival was shown for the children receiving retinoic acid.
Kohler
J A
JA
Child Health, Southampton General Hospital, Southampton, United Kingdom.
Imeson
J
J
Ellershaw
C
C
Lie
S O
SO
D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D002613:Cheilitis / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D015474:Isotretinoin / Q000009:adverse effects / Q000627:therapeutic use*; D008558:Melphalan / Q000627:therapeutic use; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000188:drug therapy / Q000473:pathology; D009447:Neuroblastoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012871:Skin Diseases / Q000139:chemically induced; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D015474:Isotretinoin; D008558:Melphalan